Bülent GÜNLÜSOY, Tansu DEĞİRMENCİ, Özgü AYDOĞDU, Yasin CEYLAN, Yusuf Kadir TOPÇU, Ertugrul ŞEFİK

PROSTAT SPESİFİK ANTİJEN 2.5-4 NG/ML ARALIĞINDA PSAD VE PROSTAT BİYOPSİ SONUÇLARININ DEĞERLENDİRİLMESİ

Amaç: Bu çalışmanın amacı; PSA 2.5- 4 ng/ml arasında olan hastaların verilerini ve bu aralıkta kanser saptama oranını değerlendirmektir. Gereç ve Yöntemler: Ocak 2011-Aralık 2014 tarihleri arasında hastanemizde Prostat Kanseri (PCa) şüphesi olan ve total PSA değeri 2.5-4 ng/ml olan 83 hastadan alınan prostat biyopsi sonuçları retrospektif olarak değerlendirildi. PSA yüksekliği ve/veya anormal rektal muayene bulgusu ile kliniğimize başvuran her hastaya transrektal ultrason eşliğinde prostat biyopsisi uygulandı. Hastaların yaşları, total PSA değerleri, PSAD, prostat volümleri, parmakla rektal muayeneleri ve prostat biyopsisi sonuçları retrospektif olarak değerlendirildi.Sonuç: Hastaların ortalama yaşı 64.1±8.3 idi. 0rtalama PSA degerleri 3.1±0.8 ng/ml idi. 16 hastada prostat kanseri saptandı. 67 hastada benign patolojiler saptandı. Prostat kanseri saptanan hastaların yaşları, PSA, PSAD, prostat volümleri sırası ile; 63.1±9.4. 3.34±0.37. 0.06±0.01, 50.1±9.6 idi. Prostat kanseri saptanmayan grupta ise bu değerler; 64.4±8.6, 3.23±0.4, 0.05±0.01, 66.1±17.7 idi. Yalnızca prostat boyutu; prostat kanseri saptanan hastalarda anlamlı olarak küçük saptandı. 22 hastada anormal rektal muayene bulgusu saptandı. 16 (%19.2) hastada prostat kanseri saptandı. Hastaların ortalama gleason skoru 6.5 idi. Tartışma: PSA 2.5-4 ng/ml aralığında kanser saptama oranımız literatürle uyumlu bulunmuştur. Bu hastaların klinik olarak tedavi edilmesi gerektiğini düşünmekteyiz. Bu nedenle 2.5 ng/ml PSA seviyesinde hastalara prostat biyopsisi yapılması gerektiği düşüncesindeyiz.

Evaluation of PSAD and Prostate Biopsy Results in Prostat Specific Antigen Between 2.5-4 ng/mL

Objective: The aim of this study; we retrospective analyzed data of the results of prostate biopsy of patients who had the prostate specific antigen (PSA) levels between 2.5- 4 ng/ml and we evaluate to the cancer detection rate in this range.Material and Methods: Between January 2011 and December 2014, prostate biopsy results from 83 patients with a total PSA level of 2.5-4 ng / mL, which were suspected to be PCA in our hospital, were evaluated retrospectively.Each patient underwent transrectal ultrasound guided prostate biopsy. The age, total PSA, prostate volume, digital rectal examination and pathology result were evaluated for each patient. Results: The mean age of the patients was 64.1 ± 8.3 . Mean PSA values were 3.1 ± 0.8 ng/ml. Prostate cancer was detected in 16 patients. Benign pathologies were detected in 67 patients. Patients with prostate cancer is detected; Ages, PSA, PSAD, prostate volumes; 63.1 ± 9.4, 3.34 ± 0.37, 0.06 ± 0.01, 50.1 ± 9.6, respectively. In the group without prostate cancer, these values were; 64.4 ± 8.6, 3.23 ± 0.4, 0.05 ± 0.01, 66.1 ± 17.7, respectively. Only small prostate size was found significant in prostate cancer patients.Abnormal digital rectal examination was found in 22(%26) patients .Prostate cancer was detected in 16 (19.2%) patients. Gleason score of Prostate cancer patients were 6.5 . Conclusion: Our cancer detection rate in PSA range 2.5-4 ng / ml was found to be consistent with the literature. We think that these cancers should also be treated clinically. For this reason we suggest to do prostate biopsy for patients who have PSA level over 2.5 ng / ml.

PDF

___

1. Printz C. Many unknowns in low-risk prostate cancer treatment. Ongoing studies and biomarker research may shed light on best approach. Cancer. 2009;115:4645-6.
2. Wang MC, Valenzuala LA, Murphy GP, Chu TM: Purification of a human prostate specific antigen. Invest Urol. 1979;17: 159.
3. Lilja II: A kallikrein like serin protease in prostatic fluid cleaves the predominant seminal vesicle protein. J Clin İnvest. 1985;76: 1899.
4. Stamey TA, Yang N, Hay AR, McNeal JE, Freiha FS, Redwine E: Prostate specific antigen as a serum marker for adenocarcinoma of the prostate. N Eng J Med. 1987;317: 909.
5. Brawer MK: Laboratory studies for the detection of carcinoma of prostate. Urol Clin North Am. 1990;17: 759-67.
6. Stamey TA: PSA in the diagnosis and treatment of adenocarcinoma of the prostate. Monogr Urol. 1989;10: 49-50.
7. Ng TK, Vasilareas D, Mitterdorfer AJ, Maher PO, Lalak A. Prostate cancer detection with digital rectal examination, prostate-specific antigen, transrectal ultrasonography and biopsy in clinical urological practice. BJU Int. 2005;95:545-8.
8. National Collaborating Centre for Cancer. Prostate cancer: diagnosis and treatment. London (UK): National Institute for Health and Care Excellence (NICE), (Clinical guideline; no. 175);2014.
9. Hodge KK, McNeal JE, Terris MK, Stamey TA. Random systematic versus directed ultrasound guided transrectal core biopsies of the prostate. J Urol. 1989;142:71-4.
10. Catalona WJ, Hudson MA, Scardino PT, Richie JP, Ahmann FR, Flanigan RC et al. Selection of optimal prostate specific antigen cutoffs for early detection of prostate cancer: re ceiver operating characteristic curves. J Urol. 1994; 152(11):2037-42.
11. Catalona WJ, Smith DS, Ornstein DK. Prostate cancer detection in men with serum PSA concentrations of 2.6 to 4.0 ng/mL and benign prostate examination. Enhancement of specificity with free PSA measurements. JAMA. 1997; 277: 1452-5.
12. Thompson IM, Pauler DK, Goodman PJ, Tangen CM, Lucia MS, Parnes HL et al. Prevalence of prostate cancer among men with a prostate specific antigen level _____ 4.0 ng per milliliter. N Engl J Med. 2004; 350: 2239- 46.
13. Gilbert SM, Cavallo CB, Kahane H, Lowe FC. Evidence suggesting PSA cutpoint of 2.5 ng/ mL for prompting prostate biopsy: review of 36,316 biopsies. Urology. 2005;65(3):549-53.
14. Bodakçı NM, Bozkurt Y, Atar M, Hatipoğlu NK, Penbegül N, Söylemez H, et al. Düşük prostat spesifik antijen değeri olan hastalara yapılan transrektal prostat biyopsi sonuçları. Dicle Tıp Mecmuası. 2012; 39 (2): 238-41.
15. Rashid M, Alam AK, Habib AK, Rahman H, Hossain AK, Salam MA, Rahman S. Efficacy of lower cut off value of serum prostate specific antigen in diagnosis of prostate cancer. Bangladesh Med Res Counc Bull. 2012;38(3):90-3.
16. Benson MC, McMahon DJ, Cooner WH. An algorithm for prostate cancer detection in a patient population using prostatespecific antigen and prostate-specific antigen density. World J Urol. 1993;11: 206-13.
17. Catalona WJ, Partin AW, Slawin KM, Brawer MK, Flanigan RC, Patel A et al. Use of the percent age of free PSA to enhance differentiation of prostate cancer from benign prostatic disease: A prospective multicenter clinical trial. JAMA. 1998;279:1542-7.
18. Yamamoto S, Kin U, Nakamura K Hamano M, Nishikawa Transperineal ultrasound-guided 12-core systematic biopsy of the prostate for patients with a prostate-specific antigen level of 2.5-20ng/ml in Japan Int J Clin Oncol. 2005; 10:117-21.